在临床环境中，副作用驱动肾移植受者改用Belatacept

Journal of clinical & experimental immunology Pub Date : 2020-02-14 DOI:10.33140/jcei.05.01.03

{"title":"在临床环境中，副作用驱动肾移植受者改用Belatacept","authors":"","doi":"10.33140/jcei.05.01.03","DOIUrl":null,"url":null,"abstract":"Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal\nimmunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney\ntransplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"46 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Side Effect Driven Conversion to Belatacept for Kidney Transplant Recipients in a Clinical Setting\",\"authors\":\"\",\"doi\":\"10.33140/jcei.05.01.03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal\\nimmunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney\\ntransplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.\",\"PeriodicalId\":73657,\"journal\":{\"name\":\"Journal of clinical & experimental immunology\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical & experimental immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/jcei.05.01.03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/jcei.05.01.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

肾移植后维持免疫抑制对移植和患者生存至关重要。然而，最佳的免疫抑制药物可能因患者的不良反应而有所不同。在这里，我们报告了73例肾移植患者由于移植后至少90天的不良反应而从他克莫司转为贝拉他接受的一年结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Side Effect Driven Conversion to Belatacept for Kidney Transplant Recipients in a Clinical Setting

Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal immunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney transplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of clinical & experimental immunology

自引率

0.00%

发文量